PubMed

QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug Development.

PMID: 41807277 · 2026

R, o, b, e, r, t, , M, , L, e, s, t, e, r, ;, , K, a, t, h, e, r, i, n, e, , C, l, a, r, k, ;, , S, a, b, i, n, a, , P, a, g, l, i, a, l, u, n, g, a

RevistaClinical and translational science

Año2026

PMID41807277

Resumen

Regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and the Japanese Pharmaceutical and Medical Device Agency (PMDA) provide scientific and public health guidance with cardiac safety being paramount in drug development of new investigational products (IP). Cardiac safety is not a singular undertaking but rather encompasses many elements to be considered beyond measurement of the QT interval before a candidate drug receives regulator

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.